Boucek R J, Dodd D A, Atkinson J B, Oquist N, Olson R D
Department of Pediatrics, University of South Florida College of Medicine, Tampa, FL 33701-4827, USA.
J Mol Cell Cardiol. 1997 Oct;29(10):2631-40. doi: 10.1006/jmcc.1997.0494.
The mechanisms for the progression of the anthracycline-induced cardiomyopathy to contractile failure has not been defined. In vitro, doxorubicin (DOX) appears to modify calcium-mediated excitation-contraction coupling, which depresses cardiac contractility. This study characterizes the onset of contractile failure associated with the development of DOX-induced cardiomyopathy. Rabbits were treated with DOX (1 mg/kg i.v. twice weekly, 12-18 doses; DOX-treated group) and compared with a pair-fed Control group infuse with saline vehicle. The severity of the cardiomyopathy was determined by numerically-scored histopathology. Myocardial contractility was determined in thin fiber bundles from right ventricular (RV) papillary muscles and left atria that were removed and mounted on a force transducer in oxygenated Krebs-bicarbonate buffer (pH=7.4 at 30 degrees C) to record the amplitude (DT) and maximum rate (+dT/dt ) of isometric tension. Myofibrillar and calcium loading properties were determined by the calcium and caffeine-activated tension responses respectively in chemically-permeabilized fibers. With the onset of the cardiomyopathy (score <2) DT at low frequency (0.5 Hz) was depressed (0.61+/-0.01 mN/mg; n=14) compared to Control (0.93+/-0.09 mN/mg; n=15). Contractility at higher rates (1 Hz) was not different in this DOX-treated and Control groups. Maximum calcium and caffeine-activated force and the pCa to half-maximum force of permeabilized fibers were comparable in DOX-treated and Control groups. The loss of contractility of the DOX-treated group was related to reduction in sarcoplasmic reticulum calcium release channel density, as determined by Bmax for 3H-ryanodine binding in cardiac microsomal membrane fraction. Post-rest potentiation of contractility, as well as frequency-dependent (0.25-1.5 Hz) and post-extrasystolic potentiation of contractility were preserved in the DOX-treated group. In vitro, DOX depressed post-rest potentiation of contractility. Thus, the onset of contractile failure of the DOX-induced cardiomyopathy is characterized by effects consistent with disordered calcium-mediated excitation-contraction coupling and these effects are qualitatively different than in vitro effects of DOX.
蒽环类药物诱导的心肌病进展为收缩功能衰竭的机制尚未明确。在体外,阿霉素(DOX)似乎会改变钙介导的兴奋-收缩偶联,从而降低心脏收缩力。本研究对与DOX诱导的心肌病发展相关的收缩功能衰竭的起始情况进行了表征。用DOX(1mg/kg静脉注射,每周两次,共12 - 18剂;DOX治疗组)对兔子进行治疗,并与输注生理盐水载体的配对喂养对照组进行比较。通过数字评分组织病理学确定心肌病的严重程度。从右心室(RV)乳头肌和左心房取出细纤维束,将其安装在含氧的Krebs - 碳酸氢盐缓冲液(30℃时pH = 7.4)中的力传感器上,以记录等长张力的幅度(DT)和最大速率(+dT/dt),从而测定心肌收缩力。分别通过化学通透纤维中钙和咖啡因激活的张力反应来测定肌原纤维和钙负载特性。随着心肌病的发生(评分<2),与对照组(0.93±0.09mN/mg;n = 15)相比,低频(0.5Hz)时的DT降低(0.61±0.01mN/mg;n = 14)。在该DOX治疗组和对照组中,较高频率(1Hz)时的收缩力没有差异。DOX治疗组和对照组中通透纤维的最大钙和咖啡因激活力以及达到最大力一半时的pCa相当。通过心脏微粒体膜部分中3H - 兰尼碱结合的Bmax测定,DOX治疗组收缩力的丧失与肌浆网钙释放通道密度的降低有关。DOX治疗组中收缩力的静息后增强以及频率依赖性(0.25 - 1.5Hz)和早搏后收缩力增强得以保留。在体外,DOX降低了收缩力的静息后增强。因此,DOX诱导的心肌病收缩功能衰竭的起始特征是与钙介导的兴奋 - 收缩偶联紊乱一致的效应,并且这些效应在性质上与DOX的体外效应不同。